Immunocompromised populations develop a lower immunogenic response to COVID-19 vaccines, leaving them at a higher risk of severe disease, hospitalization, and death. Patients with HIV who have low ...

Despite the capability of antiretroviral drugs to suppress HIV to undetectable levels, some people living with the human ...

HIV integrates into the host genome to create a persistent viral reservoir. Stimulation of CD4⁺ memory T lymphocytes with common γc-chain cytokines renders these cells more susceptible to HIV ...

Primary effectiveness was measured by the number of patients with HIV-1 RNA ≥50 copies/mL at Week 48, as well as the number of patients with a change in CD4 cell count, and the proportion of patients ...

Background. Robust immune restoration in human immunodeficiency virus (HIV)–positive patients is dependent on thymic function. However, few studies have investigated thymic function and its ...

No difference in stroke risk for HIV-positive patients Those with HIV and high CD4 cell counts had no excess risk for ischemic stroke compared with those without HIV. In a 15-year study, risk for ...

People with HIV who have moderate immune suppression appear to be at greater risk of severe COVID-19 'breakthrough' infection after vaccination, according to a new study. People with HIV who have ...

As a part of its life cycle, human immunodeficiency virus-1 (HIV-1) inserts a copy of its DNA into human immune cells. Some of these newly infected immune cells can then transition into a dormant, ...

The two-drug regimen dolutegravir/lamivudine is as effective as the three-drug regimen dolutegravir plus tenofovir ...